Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
274,650,631
-
Total 13F shares
-
158,086,076
-
Share change
-
+17,852,154
-
Total reported value
-
$354,139,573
-
Put/Call ratio
-
64%
-
Price per share
-
$2.24
-
Number of holders
-
102
-
Value change
-
+$33,881,138
-
Number of buys
-
62
-
Number of sells
-
58
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock (TSHA) as of Q2 2024
As of 30 Jun 2024,
Taysha Gene Therapies, Inc. - Common Stock (TSHA) was held by
102 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
158,086,076 shares.
The largest 10 holders included
FMR LLC, RTW INVESTMENTS, LP, Avoro Capital Advisors LLC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, MORGAN STANLEY, VANGUARD GROUP INC, Octagon Capital Advisors LP, and Artal Group S.A..
This page lists
102
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.